Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 33  |  Issue : 4  |  Page : 1123-1130

Efficacy of intravitreal injection of aflibercept in the treatment of neovascular age-related macular degeneration


Department of Ophthalmology Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt

Correspondence Address:
Basant M. M. Doma
MBBCh, Department of Ophthalmology, Faculty of Medicine, Menoufia University, Shebin El kom, Menoufia 31733
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_321_19

Rights and Permissions

Objectives To evaluate the visual and anatomical outcomes following intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration (AMD). Background Neovascular AMD is considered a principal cause of visual impairment worldwide. It is associated with choroidal neovascularization, which causes exudation that affects vision. Early clinical trials showed that intravitreal injection of anti-vascular endothelial growth factor agents is associated with significant improvement of visual outcomes in the majority of eyes. Aflibercept is an anti-vascular endothelial growth factor agent that recently gained approval for treating neovascular AMD. Patients and methods This prospective study conducted at Menoufia University Hospitals, included 60 eyes of 46 patients with treatment–naïve neovascular AMD. The patients received 3monthly aflibercept intravitreal injections. The best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure were measured at diagnosis and after each injection. Also, the patients were asked to fill the 25-item National Eye Institute Visual Function Questionnaire at baseline and at the end of the study. Results The mean BCVA improved from 0.061 (decimal fraction) to 0.081 after the third injection (P < 0.001). The mean CMT significantly decreased from 484.07 μm at baseline to 331.1 μm after the third injection (P < 0.001). No significant changes in intraocular pressure were observed during the study. There was a significant improvement in total score and some subscale scores of the 25-item National Eye Institute Visual Function Questionnaire. Conclusion Intravitreal aflibercept in neovascular AMD is associated with increased BCVA and reduced CMT. In addition, intravitreal aflibercept possibly has a benefit of improving the quality of vision-related functions.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed339    
    Printed34    
    Emailed0    
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal